Here are 1-2 brief analogies for Fate Therapeutics (FATE):

• Imagine the advanced cell therapies from Novartis or Gilead, but Fate Therapeutics is developing the 'ready-to-wear' version for broader patient access.
• Think of them as the Ford of cell therapies, aiming to mass-produce standardized, off-the-shelf cancer treatments.

• FT576: A BCMA-targeting CAR NK cell therapy currently in clinical development for multiple myeloma.
• FT522: A CD19-targeting CAR NK cell therapy currently in clinical development for B-cell lymphomas and leukemias.
• FT536: An iPSC-derived NK cell therapy engineered with a high-affinity CD16 receptor, designed to enhance antibody-dependent cellular cytotoxicity against various cancers.

Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company and sells primarily to other companies through collaboration and licensing agreements.

Its major customer is:

• Ono Pharmaceutical Co., Ltd. (TYO: 4528)

null

Bob Valamehr, Ph.D., M.B.A. President & CEO

Bahram (Bob) Valamehr was appointed President and Chief Executive Officer of Fate Therapeutics as of January 1, 2025. He previously served as the company's President of Research and Development for nearly 15 years, Chief Development Officer, and Vice President of Cancer Immunotherapy from 2016 to 2018. Prior to joining Fate Therapeutics, Dr. Valamehr held key scientific roles at Amgen, the Center for Cell Control (an NIH Nanomedicine Development Center), and the Broad Stem Cell Research Center, where his work focused on controlling pluripotency and modulating stem cell fate. He is credited with leading the development of Fate's induced pluripotent stem cell (iPSC) platform, which has resulted in numerous high-tier journal publications, over 500 issued patents, and the allowance of thirteen Investigational New Drug (IND) applications. Dr. Valamehr earned his Ph.D. from the Department of Molecular and Medical Pharmacology at UCLA, his M.B.A. from Pepperdine University, and his B.S. from the Department of Chemistry and Biochemistry at UCLA.

Kamal Adawi, M.S., M.B.A. Chief Financial Officer

Kamal Adawi was appointed Chief Financial Officer of Fate Therapeutics in October 2025. Before joining Fate Therapeutics, Mr. Adawi served as the Chief Financial Officer at Mindera Health. His prior experience includes serving as Corporate Secretary at Exagen Inc. and Chief Financial Officer at Pathway Genomics. Additionally, Mr. Adawi has held various financial leadership positions at companies such as Becton Dickinson, GenMark Dx, and Digirad Corporation.

Cindy Tahl, J.D. Chief Legal & Compliance Officer

Cindy Tahl serves as the Chief Legal & Compliance Officer at Fate Therapeutics, where she is responsible for providing legal advice, overseeing company compliance, and directing the development and expansion of the company's intellectual property portfolio. Before her tenure at Fate Therapeutics, Ms. Tahl worked as a technology transactions attorney at Wilson Sonsini Goodrich & Rosati, P.C. and practiced intellectual property law at Kenyon & Kenyon, LLP in New York. She has extensive experience working with biotechnology companies at various stages of growth, assisting clients with corporate transactions and patent strategy.

Tunde Babalola, Ph.D. Senior Vice President, Technical Operations

Tunde Babalola is the Senior Vice President of Technical Operations at Fate Therapeutics, where he is responsible for overseeing all GxP operations, process development, quality, and compliance activities. Dr. Babalola brings over 15 years of diverse experience in the fields of cell therapy, biologics, small molecules, combination products, and medical implants. Prior to joining Fate Therapeutics, he held leadership roles at Kite, A Gilead Company, where he led quality control and quality assurance site organizations for Yescarta® and Tecartus®.

Vaneet Sandhu, M.D. Vice President, Clinical Development

Vaneet Sandhu is the Vice President of Clinical Development at Fate Therapeutics, where she leads the development of the company's clinical programs focused on autoimmunity.

The emergence of robust, highly effective, and scalable alternative allogeneic cell therapy platforms that are not derived from induced pluripotent stem cells (iPSCs) presents a clear emerging threat. While Fate Therapeutics is a leader in iPSC-derived cell therapies, other companies are developing off-the-shelf cell therapies using different foundational sources, such as gene-edited primary donor cells or cord blood, combined with advanced engineering techniques. Should these alternative platforms demonstrate superior clinical efficacy, safety profiles, or manufacturing advantages (e.g., lower cost or greater ease of production) compared to iPSC-derived therapies in late-stage clinical trials, they could diminish the unique value proposition and competitive advantage of Fate Therapeutics' iPSC platform. Companies pursuing these alternative approaches include Allogene Therapeutics (gene-edited donor T-cells) and Caribou Biosciences (CRISPR-edited allogeneic CAR-T and NK cells), whose successful advancement could challenge the long-term market positioning of iPSC-based cell therapies.

FT819 (Systemic Lupus Erythematosus / B-cell Mediated Autoimmune Diseases)

FT825 (Solid Tumors)

FT522 and other programs targeting Hematologic Malignancies

Here are 3-5 expected drivers of future revenue growth for Fate Therapeutics (FATE) over the next 2-3 years:

1. Advancement and Potential Commercialization of FT819 in Autoimmune Diseases: Fate Therapeutics' lead product candidate, FT819, an off-the-shelf CAR T-cell therapy, is a significant driver of future revenue. The company received Regenerative Medicine Advanced Therapy (RMAT) designation for FT819 from the FDA in April 2025, which is expected to expedite its development and regulatory review pathway. Fate Therapeutics aims to commence a registrational study for FT819 in Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) in 2026. Promising clinical data for FT819 in these indications, demonstrating significant disease improvement with less-intensive or no conditioning, supports its potential to address substantial unmet medical needs in the autoimmune disease market.
2. Expansion of FT819 and FT839 into Additional Autoimmune Indications: Beyond SLE and LN, Fate Therapeutics plans to broaden the clinical investigation of FT819 to include other B cell-mediated autoimmune diseases such as anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc) in the second half of 2025. Additionally, the company intends to initiate clinical investigation for FT839 in autoimmunity beginning in 2026. This strategic expansion into multiple autoimmune indications represents a substantial opportunity for future revenue growth by targeting a larger patient population.
3. Progress in Solid Tumor Programs, including FT825/ONO-8250 and Collaborative Candidates: The company's pipeline includes programs for solid tumors, such as FT825/ONO-8250, an iPSC-derived CAR T-cell product candidate that has shown a favorable safety profile in initial Phase 1 clinical data. Furthermore, Fate Therapeutics has an ongoing partnership with Ono Pharmaceuticals, which is already generating revenue from preclinical development activities for a second collaboration candidate targeting an undisclosed solid tumor antigen. Continued advancement and potential future milestones or commercialization from these solid tumor programs and collaborations could contribute to revenue growth.
4. Strategic Partnerships and Collaborations: The existing collaboration with Ono Pharmaceuticals, which contributed $1.9 million in revenue in the second quarter of 2025, demonstrates the potential for revenue generation through strategic alliances. As Fate Therapeutics' proprietary induced pluripotent stem cell (iPSC) product platform and pipeline advance, establishing new partnerships or expanding existing ones could lead to additional upfront payments, research funding, milestone payments, and future royalties, thereby diversifying and increasing revenue streams.

Share Issuance

• In March 2024, Fate Therapeutics priced an underwritten offering of 14,545,454 shares of common stock at $5.50 per share and a concurrent private placement of pre-funded warrants for 3,636,364 shares, expecting gross proceeds of approximately $100.0 million.
• In June 2020, Fate Therapeutics completed a public offering of 7,108,796 shares of common stock, including the full exercise of the underwriters' option to purchase additional shares, at $28.31 per share, resulting in aggregate gross proceeds of approximately $201.3 million.
• On October 13, 2025, the Board approved an increase of an additional 1,750,000 shares to the reserve under the Inducement Plan, adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4).

Inbound Investments

• Fate Therapeutics received a $4 million award from the California Institute of Regenerative Medicine (CIRM) in January 2025 to support IND-enabling activities for its FT836 product candidate.
• In June 2022, Fate Therapeutics expanded its collaboration with Ono Pharmaceutical to include the research and development of CAR-targeted natural killer (NK) cell candidates for solid tumors. The collaboration with Ono Pharmaceutical also generates revenue from preclinical development activities for collaboration candidates.
• As of March 31, 2025, Fate Therapeutics reported $272.7 million in cash and investments, with a projected operating runway through the first half of 2027. The company reported $248.9 million in cash, cash equivalents, and investments as of June 30, 2025, extending its operating runway through the end of 2027.

Capital Expenditures

• Fate Therapeutics anticipates incurring significant operating and capital expenditures as it continues research and development, seeks regulatory approval for product candidates, in-licenses or acquires new product candidates, implements additional infrastructure and internal systems, and hires additional personnel.
• Net proceeds from the June 2020 public offering were intended to fund, among other things, the expansion of its cGMP compliant manufacturing operations, including the construction, commissioning, and qualification of its new facility.